The Impact of Beta-Blockers and Renin-Angiotensin-Aldosterone System Inhibitors on the Prognosis of Atrial Fibrillation Patients with Chronic Obstructive Pulmonary Disease: A Nation-Wide Registry Study
International Journal of Chronic Obstructive Pulmonary Disease · 2025
DOI: 10.2147/copd.s511117 ↗At a glance
Beobachtungsstudie in International Journal of Chronic Obstructive Pulmonary Disease, 2025. Written by Hanyang Liang and 8 co-authors. Institution: Department of Emergency Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease of China, National Center for Cardiovascular Diseases,…. Major MEDLINE topics: Pulmonary Disease, Chronic Obstructive, Atrial Fibrillation, Adrenergic beta-Antagonists, Angiotensin-Converting Enzyme Inhibitors. Cited 6 times so far (Crossref); 28 references. The full text is freely available (open access, CC BY-NC 3.0).
Topics: COPD
Abstract (original language)
Purpose
The management of the coexistence of chronic obstructive pulmonary disease (COPD) and atrial fibrillation (AF) remains unclear due to a lack of evidence. This study aimed to find the effect of beta-blockers and renin-angiotensin-aldosterone system inhibitors (RAASi) in this special population. Patients and Methods: We designed an observational real-world study that included 2016 AF patients from 20 hospitals across the country. The diagnosis of COPD was extracted from case report forms and confirmed by specialists. The study endpoint was all-cause mortality. Kaplan-Meier curves and Log rank test were used to analyse the prognosis of different treatments. Several multivariable Cox regression models were performed to identify the independent prognostic value of the medications.
Results
Approximately 30% of patients were prescribed beta-blockers or RAASi. Survival curves showed that beta-blockers did not affect all-cause mortality in AF patients with COPD (P=0.130). Patients with RAASi had a better prognosis than those without (P=0.011). After multivariable Cox regression analysis adjusting for demographics, other comorbidities and treatments, beta-blockers and angiotensin II receptor blockers (ARB) did not independently affect the endpoint. Angiotensin converting enzyme inhibitors (ACEI) remained a protective factor for overall survival in AF patients with COPD (model 1: HR=0.45, 95% CI 0.21-0.98, P=0.045; model 2: HR=0.41, 95% CI 0.18-0.93, P=0.034; model 3: HR=0.38, 95% CI 0.16-0.89, P=0.026).
Conclusion
Beta-blockers did not affect overall survival in patients with AF and COPD, whereas ACEI may be protective.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Emergency Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease of China, National Center for Cardiovascular Diseases, National Clinical Research Center of Cardiovascular Diseases, Chinese…
ORCID profiles: Yanmin Yang
Cite
APA
Liang, H., Tan, J., Xu, W., Lyu, S., Wu, S., Wang, J., Shao, X., Zhang, H., & Yang, Y. (2025). The Impact of Beta-Blockers and Renin-Angiotensin-Aldosterone System Inhibitors on the Prognosis of Atrial Fibrillation Patients with Chronic Obstructive Pulmonary Disease: A Nation-Wide Registry Study. International Journal of Chronic Obstructive Pulmonary Disease. https://doi.org/10.2147/copd.s511117
Vancouver
Liang H, Tan J, Xu W, Lyu S, Wu S, Wang J, et al. The Impact of Beta-Blockers and Renin-Angiotensin-Aldosterone System Inhibitors on the Prognosis of Atrial Fibrillation Patients with Chronic Obstructive Pulmonary Disease: A Nation-Wide Registry Study. International Journal of Chronic Obstructive Pulmonary Disease. 2025. doi:10.2147/copd.s511117
BibTeX
@article{Liang2025,
author = {Liang, Hanyang and Tan, Jiangshan and Xu, Wei and Lyu, Siqi and Wu, Shuang and Wang, Juan and Shao, Xinghui and Zhang, Han and Yang, Yanmin},
title = {The Impact of Beta-Blockers and Renin-Angiotensin-Aldosterone System Inhibitors on the Prognosis of Atrial Fibrillation Patients with Chronic Obstructive Pulmonary Disease: A Nation-Wide Registry Study},
journal = {International Journal of Chronic Obstructive Pulmonary Disease},
year = {2025},
doi = {10.2147/copd.s511117}
}
EUVIMED